Hematological Neoplasms

Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of cancer immunotherapy. As a chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah has set a new benchmark for treating various hematologic malignancies.

As of May 1, 2018, the FDA has approved Novartis’ CD19-targeted CAR-T therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Kymriah (tisagenlecleucel) is a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy developed by Novartis. It represents a novel approach to cancer treatment by using the patient’s own genetically modified T-cells to target and kill cancer cells.

Axicabtagene ciloleucel (axi-cel, Yescarta) and tisagenlecleucel (tisa-cel, Kymriah) were the first two CAR-T products approved in Europe for the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL) patients, and they have accumulated some real-world experience.

The ZUMA-2 study found that the CD19 CAR-T cell product Tecartus (Brexucabtagene Autoleucel, brexu-cel) demonstrated favorable efficacy and safety profiles, and other real-world studies have also confirmed its efficacy to be similar to the ZUMA-2 study.

Currently, two CAR-T products from Kite have been approved by the Food and Drug Administration (FDA) in the United States: Yescarta (Axicabtagene ciloleucel) and Tecartus (Brexucabtagene autoleucel).

Kite Pharma has been at the forefront of car-t therapy development. Two key products, yescarta (axicabtagene ciloleucel) and tecartus (brexucabtagene autoleucel), have been approved for use in many regions of the world.